APA (7th ed.) Citation

Cholon, D. M., Aleksandrov, L. A., Quinney, N. L., Boyles, S. E., Jensen, T. J., Aleksandrov, A. A., & Gentzsch, M. (2025). Implications for cystic fibrosis therapy: Potentiator icenticaftor is superior to ivacaftor in improving function and maintaining stability of F508del CFTR. Science Progress, 108(4), 1. https://doi.org/10.1177/00368504251384892

Chicago Style (17th ed.) Citation

Cholon, Deborah M., Luba A. Aleksandrov, Nancy L. Quinney, Susan E. Boyles, Timothy J. Jensen, Andrei A. Aleksandrov, and Martina Gentzsch. "Implications for Cystic Fibrosis Therapy: Potentiator Icenticaftor Is Superior to Ivacaftor in Improving Function and Maintaining Stability of F508del CFTR." Science Progress 108, no. 4 (2025): 1. https://doi.org/10.1177/00368504251384892.

MLA (9th ed.) Citation

Cholon, Deborah M., et al. "Implications for Cystic Fibrosis Therapy: Potentiator Icenticaftor Is Superior to Ivacaftor in Improving Function and Maintaining Stability of F508del CFTR." Science Progress, vol. 108, no. 4, 2025, p. 1, https://doi.org/10.1177/00368504251384892.